Bloqueadores Alfa

<p>Applications Piperazine derivative used as reference materials for forensic laboratories. They affect the central and the autonomic nervous systems, the blood pressure, and smooth muscle.<br>References Brady, J., et al.: Drug Dev. Res., 20, 231 (1990), Winter, J., et al.: J. Pharmacol. Exp. Ther., 262, 682 (1992), Ator, N., et al.: Eur. J. Pharmacol., 241, 237 (1993), Forster, E., et al.: Eur. J. Pharmacol., 281, 81 (1995),<br></p>

<p>Applications 2-Phenylphenol is an agricultural fungicide and is no longer used as a food additive (1). It has been associated with the incidence of bladder cancer in male rats which may be related to its primary metabolite, phenylhydroquinone (2). Drinking water contaminant candidate list 3 (CCL 3) compound as per United States Environmental Protection Agency (EPA). Environmental contaminants; Food contaminants.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References 1. Gouin T. et al.: Environ Pollut. 2012 Jun;165:208-14. 2. Balakrishnan, S. et al.: Environ Mol Mutagen. 2016 Apr;57(3):210-9<br></p>

<p>Applications 2-(4-Methyl-2-phenyl-1-piperazinyl)-3-pyridinemethanol is an impurity found in Mirtazapine (M365000). Mirtazapine Impurity B.<br></p>

<p>Applications An optically active metabolite of Carvedilol (C184625), a nonselective ß-adrenergic blocker with α1-blocking activity.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., ET AL.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Schaefer, W.H., et al.: Drug Metab. Dispos., 26, 10, 958 (1998),<br></p>

<p>Applications (R)-Tamsulosin is a specific α1-adrenoceptor antagonist. It is used in the treatment of benign prostatic hypertrophy.<br>References Kawabe, K., et al.: J. Urol., 144, 908 (1990), Abrams, P., et al.: Br. J. Urol., 76, 325 (1995), Michel, M.C., Expert Opin. Pharmacother., 5, 151 (2004),<br></p>

<p>Impurity Alfuzosin Hydrochloride EP Impurity E<br>Applications Alfuzosin (A532000) impurity. Alfuzosin (A532000) is an α1-Adrenoceptor antagonist structurally similar to Prozosin. Antihypertensive. Used in treatment of benign prostatic hypertrophy. (Alfuzosin Hydrochloride EP Impurity E )<br>References Ramage, A.G., et al.: Eur. J. Pharmacol., 129, 307 (1986), Deering, A.H.,: Brit. J. Clin. Pharmacol., 25, 417 (1988), Priolo, L.D., et al.: Eur. J. Clin. Pharmacol., 35, 25 (1988),<br></p>

<p>Applications 3-(9H-Carbazol-4-yloxy)-1,2-propanediol is used in the synthesis of carvedilol, a β-adrenergic blocking agent.<br>References Naidu, K. et al.: Org. Chem. An Indian J., 6, 171 (2010);<br></p>

<p>Applications Tamsulosin is a specific α1-adrenoceptor antagonist. Used in the treatment of benign prostatic hypertrophy.<br>References Kawabe, K., et al.: J. Urol., 144, 908 (1990), Abrams, P., et al.: Br. J. Urol., 76, 325 (1995), Michel, M.C., Expert Opin. Pharmacother., 5, 151 (2004),<br></p>

<p>Applications Mirtazapine N-Glucuronide is a metabolite of Mirtazapine (M365000), an α2-Adrenergic blocker; analogue of Mianserin. Antidepressant.<br>References Smith, D.A., RSC Drug Discovery Series, 1, 193 (2010); De Boer, T., et al.: Neuropharmacology, 27, 399 (1988); Smith, W.T., et al.: Psychopharmacol. Bull., 26, 191 (1990)<br></p>

<p>Applications S-Mirtazapine is an enantiomer of Mirtazapine (M365000); an antidepressant. R-Mirtazapine showed antinociceptive effects in acute thermal nociception, whereas S-Mirtazapine showed pronociceptive effects.<br>References Muth-Selbach, Uta., et al.: Brain Res. Bull., 79(1), 63-68 (2009); Smith, Donald F., et al.: Psychopharmacology, 200(2), 273-279 (2008); Freynhagen, Rainer., et al.: Brain Res. Bull., 69(2), 168-173 (2006)<br></p>

<p>Applications Carvedilol (C184625) derivative.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br></p>

<p>Applications Carvedilol is a nonselective β-adrenergic blocker with α1-blocking activity. Carvedilol is an antihypertensive used in the treatment of congestive heart failure.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Hirohashi, M., et al.: Arzneim.-Forsch., 40, 735 (1990); Packer, M., et al.: N. Engl. J. Med., 334, 1349 (1996);<br></p>

<p>Tamsulosin: an alpha1A blocker for easing urination in BPH by relaxing prostate and bladder muscles.</p>

<p>Stability Hygroscopic<br>Applications The optically active isomer of Carvedilol (C184625), a nonselective ß-adrenergic blocker with a1-blocking activity. An antihypertensive used in the treatment of congestive heart failure.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Hirohashi, M., et al.: Arzneim.-Forsch., 40, 735 (1990),<br></p>

<p>Impurity Carvedilol EP Impurity D; Carvedilol USP-D<br>Applications 4-(2,3-Epoxypropoxy)carbazole (Carvedilol EP Impurity D; Carvedilol USP-D) is an intermediate in the synthesis of Carvedilol (C184625).<br></p>

<p>Applications A metabolite of Mirtazapine (M365000). This compounds contains some of the alpha anomer.<br>References Sandker, G., et al.: Xenobiotica, 24, 143 (1994), Dahl, M., et al.: Clin. Drug Invest., 13, 37 (1997),<br></p>

<p>Impurity Tamsulosin EP Impurity E<br>Applications 5-Formyl-2-methoxy-benzenesulfonamide (Tamsulosin EP Impurity E) is an impurity of Tamsulosin (T006350), a specific α1-adrenoceptor antagonist used in the treatment of benign prostatic hypertrophy.<br>References Kawabe, K., et al.: J. Urol., 144, 908 (1990), Abrams, P., et al.: Br. J. Urol., 76, 325 (1995), Michel, M.C., Expert Opin. Pharmacother., 5, 151 (2004),<br></p>

<p>Impurity Tamsulosin EP Impurity F<br>Applications 2-(2-Ethoxyphenoxy)ethanamine (Tamsulosin EP Impurity F) is an impurity of Tamsulosin (T006350), a specific α1-adrenoceptor antagonist (1,2). It is used in the treatment of benign prostatic hypertrophy.<br>References 1. Kawabe, K. et al.: J. Urol. 1990 Oct;144(4):908-11;2. Abrams, P. et al.: Br. J. Urol. 1995 Sep;76(3):325-36.<br></p>